Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037901 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Inmagene.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT07037901 is a Phase 2 study of Atopic Dermatitis and Eczema that is actively recruiting participants, run by Inmagene. The registered enrollment target is 220 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07037901, a Phase 2 study of Atopic Dermatitis and Eczema, is actively recruiting participants, sponsored by Inmagene.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMG-007
Study Locations (20)
New York
- Forest Hills Dermatology Group - Kew Gardens
- Inmagene Site 1 - New York
- Vitality Clinical Trials LLC - Woodbury
California
- Antelope Valley Clinical Trials - Lancaster
- UCLA Division of Dermatology - Los Angeles
Florida
- Renstar Medical Research - Ocala
- Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research - Tampa
Ohio
- ClinOhio Research Services LLC. - Columbus
- Apex Clinical Research Center - Mayfield Heights
British Columbia
- Dr. Chin-ho-Hong Medical Inc. - Surrey
- PacificDerm - Vancouver
Ontario
- Sudbury Skin Clinique - Greater Sudbury
- DermEdge Research - Mississauga
Illinois
- Arlington Dermatology - Rolling Meadows
North Carolina
- Darst Dermatology - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07037901
The ClinicalTrials.gov registry entry for NCT07037901 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (64% lower). The listed sponsor is Inmagene, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037901 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07037901 about?
NCT07037901 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
What is the current status of trial NCT07037901?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2025-06-17. Estimated completion is 2027-10.
What conditions does trial NCT07037901 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Atopic Dermatitis Eczema.
What interventions are being tested in trial NCT07037901?
The interventions under investigation include: Placebo (DRUG), IMG-007 (DRUG).
Who is sponsoring clinical trial NCT07037901?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037901 being conducted?
This trial has 20 study locations across California, Florida, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.